Stock 6785 ALAR PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Alar Pharmaceuticals Inc.

Equities

6785

TW0006785009

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
285 TWD +1.97% Intraday chart for Alar Pharmaceuticals Inc. +3.64% +36.04%
05-10 Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-14 Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Alar Pharmaceuticals Inc. Has Received Notice of Allowance for Patent in Taiwan
CI
Alar Pharmaceuticals Inc. Approves Dividend Distribution for the Year Ended December 31, 2023, Payable on June 28, 2024
CI
Gilva Therapeutics, INC. announced that it expects to receive TWD 30 million in funding from Alar Pharmaceuticals Inc.
CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from United States Patent and Trademark Office
CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Japan Patent Office
CI
Alar Pharmaceuticals Inc. Receives Notice of Allowance for the Patent Ketamine Pamoate and Use Thereof from Instituto Mexicano De La Propiedad Industrial
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Indivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals
CI
Alar Pharmaceuticals Inc.(TPEX:6785) added to S&P Global BMI Index
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Alar Pharmaceuticals Inc. Announces Significant Progress on Developing Long-acting Buprenorphine Injectable ALA-1000
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Alar Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Alar Presents Positive Interim Results of Long-Acting Buprenorphine Injectable in Opioid Dependent Patients
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 6785 Stock
  4. News Alar Pharmaceuticals Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW